TÜBINGEN, Germany, January 6, 2016 – CureVac, a clinical-stage biopharmaceu-tical company pioneering the field of mRNA-based technology, today announced that the company will present at the 34th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will provide an overview of the company’s business, industry-leading mRNA technology platform and clinical-stage development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Dr. Hoerr will for the first time present data from the first-ever clinical proof-of-concept trial of an mRNA-based prophylactic vaccine.
Event: 34th Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 12, 2016
Time: 02:00 PM - 02:25 PM (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA.
Room: Elizabethan C
2015 was a transformative year for CureVac, highlighted by the largest equity investment of the Gates Foundation completed in March and the company’s recent $110M financing (completed November 2015), the publication of peer-reviewed studies validating its mRNA technology platform, and the establishment of collaborative agreements including those with IAVI (International AIDS Vaccine Initiative), the Bill & Melinda Gates Foundation and numerous vaccine-development projects.
In 2016 CureVac anticipates achieving multiple clinical and operational milestones, including the reporting of clinical data from its placebo controlled double blinded Phase IIb clinical trial of CV9104 in patients with prostate cancer, the start of construction of an industrial scale GMP production facility with 30 million dose/year capability, and the initiation of new clinical programs including those in collaboration with Boehringer Ingelheim and IAVI.